Company news

Celularity Inc. news in 2024

Celularity Inc.'s news releases, calls and decks from 2024, newest first.

View company

Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter

December 9, 2024

Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023

December 5, 2024

Celularity Inc. Announces Receipt of Nasdaq Notification

November 26, 2024

Celularity’s Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific

November 19, 2024

Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million

November 6, 2024

Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel

October 22, 2024

Celularity Provides Corporate Update

October 21, 2024

Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal

October 17, 2024

Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.

October 15, 2024

Celularity to Present at H.C. Wainwright’s 26th Annual Global Investment Conference

September 4, 2024

Celularity Appoints Richard J. Berman to its Board of Directors

August 27, 2024

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

August 22, 2024

Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023

July 30, 2024

SANUWAVE Provides Corporate Update

June 3, 2024

Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting

June 2, 2024

Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy

May 13, 2024

Celularity Inc. to Host Investor and Analyst Research & Development Day

April 21, 2024

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

April 18, 2024

Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024

April 17, 2024

Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products

April 14, 2024

Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells

April 7, 2024

Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L

March 25, 2024

Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy

March 19, 2024

Celularity CEO to Present on Cell Therapy’s Potential to Improve Longevity at 2024 ABUNDANCE Summit

March 13, 2024

Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress

March 11, 2024

Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells

March 6, 2024

Celularity Announces 1-for-10 Reverse Stock Split

February 22, 2024

Celularity’s Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease

February 13, 2024

Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline

January 31, 2024

Celularity and Genting Leaders Comments on Closing $21 Million Financing Transactions

January 24, 2024

Celularity Releases CEO Letter to Shareholders

January 17, 2024

Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare

January 3, 2024

Celularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023

January 2, 2024

Decks in 2024